Given that the mechanism of action of SAS involves the inhibition of SLC7A11 activity, and our study has also demonstrated that 131I can downregulate the expression of SLC7A11, we posited that their synergistic effects arose from dual targeting of this cystine/glutamate antiporter. Here, SLC7A11 is linked to SATB2 associated disorder.